According to a recent LinkedIn post from Sequel Med Tech, the company is highlighting the launch of an integrated offering that combines its twiist automated insulin delivery (AID) system with Senseonics’ Eversense 365 continuous glucose monitoring (CGM) technology, with data management powered by Tidepool. The post suggests that twiist is the first AID system compatible with Eversense 365, which is described as the only CGM designed for up to one year of continuous use, targeting people with diabetes and aiming to reduce the burden of frequent sensor replacements and device re-pairing.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post highlights that twiist is indicated for people with Type 1 diabetes ages 6 and older in the U.S., while Eversense 365 is indicated for adults 18 and older, positioning the integrated solution within a defined regulatory and clinical scope. For investors, this development points to Sequel Med Tech’s strategy to compete in the growing AID and CGM ecosystem through interoperability and longer-wear sensor technology, which could enhance product differentiation, support recurring revenue models tied to diabetes management, and potentially strengthen its standing in the broader digital health and medtech landscape if adoption scales among patients and providers.